



### PATIENT DETAILS

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
 Address: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Medicare: \_\_\_\_\_

### DIAGNOSTIC SERVICE REQUEST - Please tick one (Medicare criteria on reverse)

#### Medicare Eligible PET Examinations

with whole body diagnostic CT (Head, Chest, Abdomen, and Pelvis)

PET with non diagnostic CT (Attenuation correction only)

#### BREAST

- Staging of locally advanced (Stage III) breast Ca [61524]
- Suspected metastatic or recurrent [61525]

#### LUNG

- Solitary Pulmonary Nodule [61523]
- Non-Small Cell Lung Cancer - Staging [61529]

#### LYMPHOMA

- HL or NHL, initial staging [61620]
- HL or NHL, assess response to first line therapy [61622]
- HL or NHL, restaging [61628]
- HL or NHL, assess response to second line chemo [61632]

#### PROSTATE

- PSMA (Ga<sup>68</sup>) initial staging [61563]
- PSMA (Ga<sup>68</sup>) restaging [61564]

#### MELANOMA

- Melanoma [61553]

#### HEAD & NECK

- Head and Neck Ca, staging [61598]
- Suspected residual Ca [61604]

#### CARCINOMA

- Metastatic SCC [61610]
- Colorectal Carcinoma [61541]
- Oesophageal or GEJ carcinoma [61577]
- Ovarian carcinoma [61565]
- Uterine cervix carcinoma, primary staging [61571]
- Uterine cervix carcinoma, recurrent Ca [61575]

#### NEUROENDOCRINE

- DOTA (Ga<sup>68</sup>) for evaluation of NETs [61647]

#### SARCOMA

- Initial staging [61640]
- Suspected residual or recurrent [61646]

#### OTHER

- Rare and uncommon cancer, initial staging and management [61612]

#### Medicare Eligible PET

with diagnostic brain CT

PET with non diagnostic CT (Attenuation correction only)

#### BRAIN

- Alzheimer's Disease [61560]
- Malignant Brain Tumour [61538]
- Refractory Epilepsy (evaluated for surgery) [61559]

#### Non-Medicare Eligible PET

with whole body diagnostic CT (Head, Chest, Abdomen, and Pelvis)

PET with non diagnostic CT (Attenuation correction only)

- PSMA (Ga<sup>68</sup>) for evaluation of prostate Ca
- DOTA (Ga<sup>68</sup>) for evaluation of NETs
- Any other Unfunded <sup>18</sup>F<sup>18</sup>FDG Study

### REFERRAL DETAILS - Reason for referral and Clinical History

Primary Disease Site: \_\_\_\_\_  
 Histopathology: \_\_\_\_\_  
 Surgery Type: \_\_\_\_\_  
 Chemotherapy - Last: \_\_\_\_\_ Next: \_\_\_\_\_  
 Radiotherapy - Last: \_\_\_\_\_ Next: \_\_\_\_\_  
 Previous PET Scan: Y / N Location: \_\_\_\_\_

Please advise if the patient is:  Diabetic  Renal Function Impaired  Pregnant  Breastfeeding  Infection Precaution

### REQUESTING PRACTITIONER

Name, provider number, address, phone, fax

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

### RESULTS - Copy to:

FOR APPOINTMENT PLEASE PHONE  
**1300 788 508**

Brindabella Specialist Centre  
 5 Dann Close, Garran

pet@cig.com.au

BREAST		
Staging of locally advanced (Stage III) breast Ca	61524	BREAST CANCER, Stage III, Whole body FDG PET study performed for the staging of locally advanced (Stage III) breast cancer in a patient considered potentially suitable for active therapy.
Suspected metastatic or recurrent	61525	BREAST CANCER, Whole body FDG PET study performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma in a patient considered suitable for active therapy.
LUNG		
Solitary Pulmonary Nodule	61523	SOLITARY PULMONARY NODULE evaluation, Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
Non-Small Cell Lung Cancer - Staging	61529	NON-SMALL CELL LUNG CANCER, Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
LYMPHOMA		
HL or NHL, initial staging	61620	HL or NHL, Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma.
HL or NHL, assess response to first line therapy	61622	HL or NHL, Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma.
HL or NHL, restaging	61628	HL or NHL, Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma.
HL or NHL, assess response to second line chemo	61632	HL or NHL, Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma.
HEAD & NECK		
Head and Neck Ca, staging	61598	HEAD and NECK CANCER, Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer.
Suspected residual Ca	61604	HEAD and NECK CANCER, Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.
CARCINOMA		
Metastatic SCC	61610	METASTATIC SCC, Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
Colorectal Carcinoma	61541	COLORECTAL CARCINOMA, Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
Oesophageal or GEJ carcinoma	61577	OESOPHAGEAL or GEJ CARCINOMA, Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy.
Ovarian carcinoma	61565	OVARIAN CARCINOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
Uterine cervix carcinoma, primary staging	61571	UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
Uterine cervix carcinoma, recurrent Ca	61575	UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
SARCOMA		
Initial staging	61640	SARCOMA, Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
Suspected residual or recurrent	61646	SARCOMA, Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.
PROSTATE		
PSMA (Ga <sup>68</sup> ) initial staging	61563	<sup>68</sup> Ga - PSMA, Whole body PSMA PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent. Medicare benefits are payable for a maximum of one service in the patient's lifetime.
PSMA (Ga <sup>68</sup> ) restaging	61564	<sup>68</sup> Ga - PSMA, Whole body PSMA PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who has undergone prior locoregional therapy and is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation. This item can be claimed by patients with a prostate specific antigen (PSA) increase of 2ng/ml above the nadir after radiation therapy; or failure of PSA levels to fall to undetectable levels; or rising PSA serum after a radical prostatectomy. Medicare benefits are payable for a maximum of two services in the patient's lifetime.
BRAIN		
Alzheimer's Disease	61560	ALZHEIMER'S DISEASE, FDG PET study of the brain, performed for the diagnosis of Alzheimer's Disease, if: <ul style="list-style-type: none"> <li>a) clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and</li> <li>b) the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and</li> <li>c) a service to which this item applies has not been performed on the patient in the previous 12 months; and</li> <li>d) a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer's disease.</li> </ul> Applicable not more than 3 times per lifetime
Malignant Brain Tumour	61538	MALIGNANT BRAIN TUMOUR, FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
Refractory Epilepsy (evaluated for surgery)	61559	REFRACTORY EPILEPSY, FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.
MELANOMA		
Melanoma	61553	MELANOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
NEUROENDOCRINE		
DOTA (Ga <sup>68</sup> ) for evaluation of NETs	61647	<sup>68</sup> Ga - DOTA, Whole body PET study if: <ul style="list-style-type: none"> <li>a) a gastro-entero-pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or</li> <li>b) both (i) a surgical amenable gastro-entero-pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and (ii) the study is for excluding additional disease sites.</li> </ul>
OTHER		
Rare and uncommon cancer	61612	Rare and uncommon cancer, Whole body FDG PET study for the initial staging of eligible cancer types, for a patient who is considered suitable for active therapy, if: <ul style="list-style-type: none"> <li>a) the eligible cancer type is: <ul style="list-style-type: none"> <li>(i) a rare or uncommon cancer (less than 12 cases per 100,000 persons per year); and</li> <li>(ii) a typically FDG avid cancer; and</li> </ul> </li> <li>b) there is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient</li> </ul> Applicable once per cancer diagnosis